Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
 

Online Report Subscribers, Click Here

Pricing and Ordering Information

 

U.S. Markets for Diagnostic Oncology-Related X-Ray-Based Imaging Products
Report #A414
- March 2013
235 Pages – 47 Exhibits – 14 Company Profiles


Cancer is the second-leading cause of death in the United States (U.S.) after heart disease. It is estimated that nearly 1.7 million people in the country will be diagnosed with cancer in 2013, and that approximately 580,350 will die from the disease. In the fight against cancer, X-ray-based imaging modalities allow physicians to detect malignancies at their earliest and most treatable stages.

In 2012, approximately 279.4 million diagnostic oncology-related X-ray-based imaging procedures—including conventional X-ray, computed tomography (CT), and mammography—were performed in the U.S. Together, these procedures (performed with and without contrast agents) generated nearly $3.3 billion in corresponding product sales. It is expected that during the forecast period covered by this report, sales of X-ray-based imaging products for diagnostic oncology indications will increase at a compound annual rate of 3.5%, reaching more than$3.9 billion in the year 2017.

This dynamic, new report from Medtech Insight includes analyses of products, current and forecast markets, competitors, and opportunities in the U.S. diagnostic oncology-related X-ray-based imaging products arena.

Covered topics in this report include an overview of cancer in the U.S. including discussions on the different forms of the disease, risk factors for disease development, disease diagnosis, and statistics covering new cancer cases, cancer prevalence, and deaths due to cancer; computer-aided detection; conventional X-ray-based imaging detectors and systems, and procedure and sales volumes; CT detectors and systems, and procedure and sales volumes; digital versus screen-film devices for X-ray detection and image preservation; mammography systems, and procedure and sales volumes; oncology-related X-ray-based imaging contrast agents, procedure and sales volumes, and tomosynthesis for breast and chest imaging applications; among others.

Ordering Information

Title

Report# Publication
Date
List Price

U.S. Markets for Diagnostic Oncology-Related X-Ray-Based Imaging Products

A414

March 2013

$3,750

Order Online:
Single User only (Please call for corporate subscription pricing)
PDF Only

Print versions of Reports are available upon request for an additional fee.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

 

TABLE OF CONTENTS

 

EXECUTIVE SUMMARY

i.       New Cancer Cases, Cancer Prevalence, and Deaths Due to Cancer

ii.       Diagnostic Oncology-Related X-Ray-Based Imaging Procedures

iii.      Diagnostic Oncology-Related X-Ray-Based Imaging Products

a.      Conventional X-Ray-Based Imaging Systems

i.       Market Forecast

b.      Mammography Systems

i.       Market Forecast

c.      Computed Tomography Systems

i.       Market Forecast

d.      Contrast Media for X-Ray-Based Imaging

i.       Market Forecast

iv.      Methodology

 

Exhibit ES-1:    Estimated New Cases, Prevalence, and Deaths for Selected Types of Cancer

Exhibit ES-2:    X-Ray-Based Imaging, Combined Procedure Volumes  Forecast, 2012-2017

Exhibit ES-3:    Diagnostic Oncology-Related X-Ray-Based Imaging, Combined Procedure Volumes Forecast, 2012-2017

Exhibit ES-4:    X-Ray-Based Imaging Systems, Combined Market Forecast,  2012-2017

Exhibit ES-5:    Diagnostic Oncology-Related X-Ray-Based Imaging Products, Combined Market Forecast,  2012-2017

Exhibit ES-6:    Conventional X-Ray-Based Imaging Systems, Market Forecast, 2012-2017

Exhibit ES-7:    Mammography Systems, Market Forecast, 2012-2017

Exhibit ES-8:    Computed Tomography Systems, Market Forecast, 2012-2017

Exhibit ES-9:    Oncology-Related X-Ray-Based Imaging Contrast Agents, Market Forecast, 2012-2017

 

1. CANCER STATISTICS UPDATE

1.1 Acquired Capabilities of Cancer Cells

1.2 Cataloging Genomic Alterations Involved in the Development of Cancer

1.3 Risk Factors Associated with the Development of Cancer

1.4 Cancer Staging

1.5 New Cancer Cases, Cancer Prevalence, and Deaths Due to Cancer

1.6 Clinical and Statistical Data for Selected Types of Cancer

1.6.1 Brain and Other Nervous System Cancers

1.6.1.1 Etiology

1.6.1.2 Epidemiology

1.6.2 Breast Cancer

1.6.2.1 Etiology

1.6.2.2 Epidemiology

1.6.3 Colorectal Cancer

1.6.3.1 Etiology

1.6.3.2 Epidemiology

1.6.4 Kidney/Renal Pelvis Cancer

1.6.4.1 Etiology

1.6.4.2 Epidemiology

1.6.5 Leukemia

1.6.5.1 Etiology

1.6.5.2 Epidemiology

1.6.6 Lung/Bronchus Cancer

1.6.6.1 Etiology

1.6.6.2 Epidemiology

1.6.7 Lymphoma

1.6.7.1 Etiology

1.6.7.2 Epidemiology

1.6.8 Melanoma

1.6.8.1 Etiology

1.6.8.2 Epidemiology

1.6.9 Oral Cavity and Pharyngeal Cancers

1.6.9.1 Etiology

1.6.9.2 Epidemiology

1.6.10 Ovarian Cancer

1.6.10.1 Etiology

1.6.10.2 Epidemiology

1.6.11 Pancreatic Cancer

1.6.11.1 Etiology

1.6.11.2 Epidemiology

1.6.12 Prostate Cancer

1.6.12.1 Etiology

1.6.12.2 Epidemiology

1.6.13 Thyroid Cancer

1.6.13.1 Etiology

1.6.13.2 Epidemiology

1.6.14 Urinary Bladder Cancer

1.6.14.1 Etiology

1.6.14.2 Epidemiology

1.6.15 Uterine Cancer

1.6.15.1 Etiology

1.6.15.2 Epidemiology

 

Exhibit 1-1:      Estimated New Cases, Prevalence, and Deaths for Selected Types of Cancer

Exhibit 1-2:      Brain and Other Nervous System Cancers, Facts And Figures

Exhibit 1-3:      Breast Cancer, Facts And Figures

Exhibit 1-4:      Colorectal Cancer, Facts And Figures

Exhibit 1-5:      Kidney/Renal Pelvis Cancers, Facts And Figures

Exhibit 1-6:      Leukemia, Facts and Figures

Exhibit 1-7:      Lung/Bronchus Cancer, Facts And Figures

Exhibit 1-8:      Hodgkin Lymphoma, Facts and Figures

Exhibit 1-9:      Non-Hodgkin Lymphoma, Facts and Figures

Exhibit 1-10:    Melanoma, Facts and Figures

Exhibit 1-11:    Oral Cavity and Pharyngeal Cancers, Facts and Figures

Exhibit 1-12:    Ovarian Cancer, Facts and Figures

Exhibit 1-13:    Pancreatic Cancer, Fact and Figures

Exhibit 1-14:    Prostate Cancer, Facts And Figures

Exhibit 1-15:    Thyroid Cancer, Fact and Figures

Exhibit 1-16:    Urinary Bladder Cancer, Fact and Figures

Exhibit 1-17:    Cancer of the Uterine Corpus, Facts and Figures

Exhibit 1-18:    Cancer of the Uterine Cervix, Facts and Figures

 

2. U.S. MARKETS FOR DIAGNOSITIC ONCOLOGY-RELATED X-RAY BASED IMAGING PRODUCTS

2.1 Conventional X-Ray-Based Imaging Systems, Market Analysis

2.1.1 Technologies

2.1.2 Procedure Volumes

2.1.3 Products

2.1.4 Market Forecast

2.1.5 Competitive Analysis

2.2 Mammography Systems, Market Analysis

2.2.1 Technologies

2.2.2 Procedure Volumes

2.2.3 Products

2.2.4 Market Forecast

2.2.5 Competitive Analysis

2.3 Computed Tomography Systems, Market Analysis

2.3.1 Technologies

2.3.2 Procedure Volumes

2.3.3 Products

2.3.4 Market Forecast

2.3.5 Competitive Analysis

2.4 Contrast Media for X-Ray-Based Imaging, Market Analysis

2.4.1 Types of Contrast Media

2.4.2 Procedure Volumes

2.4.3 Products

2.4.4 Market Forecast

2.4.5 Competitive Analysis

 

Exhibit 2-1:      X-Ray-Based Imaging, Combined Procedure Volumes Forecast, 2012-2017

Exhibit 2-2:      Diagnostic Oncology-Related X-Ray-Based Imaging, Combined Procedure Volumes Forecast, 2012-2017

Exhibit 2-3:      X-Ray-Based Imaging Systems, Combined Market Forecast, 2012-2017

Exhibit 2-4:      Diagnostic Oncology-Related X-Ray-Based Imaging Products, Combined Market Forecast, 2012-2017

Exhibit 2-5:      Conventional X-Ray-Based Imaging, Procedure Volumes Forecast, 2012-2017

Exhibit 2-6:      2013, Selected Conventional X-Ray-Based Imaging Systems

Exhibit 2-7:      Conventional X-Ray-Based Imaging Systems, Market Forecast, 2012-2017

Exhibit 2-8:      2012, Conventional X-Ray-Based Imaging Systems Market, Share by Supplier

Exhibit 2-9:      Mammography, Procedure Volumes Forecast, 2012-2017

Exhibit 2-10:    2013, Selected Mammography Systems

Exhibit 2-11:    Digital Mammography Systems, Installed Base, 2004-2012

Exhibit 2-12:    Mammography Systems, Market Forecast, 2012-2017

Exhibit 2-13:    2012, Mammography Systems Market, Share by Supplier

Exhibit 2-14:    Computed Tomography, Procedure Volumes Forecast, 2012-2017  2-73

Exhibit 2-15:    2013, Selected Computed Tomography Systems

Exhibit 2-16:    Computed Tomography Systems, Market Forecast, 2012-2017

Exhibit 2-17:    2012, Computed Tomography Systems Market, Share by Supplier

Exhibit 2-18:    Contrast-Enhanced Oncology-Related X-Ray-Based Imaging, Procedure Volumes Forecast, 2012-2017

Exhibit 2-19:    Oncology-Related X-Ray-Based Imaging Contrast Agents, Market Forecast, 2012-2017

Exhibit 2-20:    2012, Oncology-Related X-Ray-Based Imaging Contrast Agents Market, Share by Supplier

 

3. COMPANY PROFILES

3.1       Bayer HealthCare Pharmaceuticals, Inc./ Bayer HealthCare LLC/Bayer AG

3.2       Bracco Diagnostics, Inc./Bracco Imaging SPA/Bracco SPA/Bracco

3.3       Carestream Health, Inc./Onex Corporation

3.4       Fujifilm Medical Systems USA, Inc./ Fujifilm Holdings America Corporation/Fujifilm

3.5       GE Healthcare, Inc./General Electric Company

3.6       Hitachi Medical Systems America, Inc./ Hitachi Medical Corporation/Hitachi LTD

3.7       Hologic, Inc.

3.8       KUB Technologies, Inc.

3.9       Mallinckrodt, Inc./Covidien LTD

3.10     Philips Healthcare, Inc./Royal Philips Electronics NV

3.11     Samsung Electronics America, Inc./ Samsung Electronics Co., LTD/Samsung

3.12     Shimadzu Medical Systems, Inc./Shimadzu Corporation

3.13     Siemens Healthcare/Siemens Medical Solutions USA, Inc./Siemens AG

3.14     Toshiba America Medical Systems, Inc./Toshiba Corporation

 

APPENDIX: COMPANY LISTING

 

To order reports or obtain information about special pre-publication offers from within the U.S., contact custcare@informa.com. You can also call 1.908.748.1221 (or toll-free within the U.S. at 1.888.670.8900) or fax 1.646.666.9878.

 

The Newsletter | The Principals | Reports | Conferences | Physician Surveys | Consulting | Contact Us | Home